Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer

PURPOSE AND METHODS: Our secondary analyses compared survival with eribulin versus capecitabine in various patient subgroups from a phase 3, open-label, randomized study. Eligible women aged ≥18 years with advanced/metastatic breast cancer and ≤3 prior chemotherapies (≤2 for advanced/metastatic dise...

Descripción completa

Detalles Bibliográficos
Autores principales: Twelves, Chris, Awada, Ahmad, Cortes, Javier, Yelle, Louise, Velikova, Galina, Olivo, Martin S., Song, James, Dutcus, Corina E., Kaufman, Peter A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4927108/
https://www.ncbi.nlm.nih.gov/pubmed/27398025
http://dx.doi.org/10.4137/BCBCR.S39615

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4927108/
https://www.ncbi.nlm.nih.gov/pubmed/27398025
http://dx.doi.org/10.4137/BCBCR.S39615

Ejemplares similares